←
Novartis13,265 posts
Novartis avatar✓

Novartis ✓

@Novartis

An innovative medicines company working to reimagine medicine. See our community guidelines: go.novartis.social/4bqbjuA

◷ Joined November 2008▧ 1,826 Photos and videos
Novartis avatar
Novartis@Novartis·Oct 27

Novartis delivered solid sales growth and core margin expansion in Q3, as priority brands and launches more than offset generic erosion. We have raised our full-year 2026 guidance* for core operating income. Link to press release: novartis.social/6018aLrvy #NVSQ326

0:20
Novartis avatar
Novartis@Novartis·Oct 27

#NVSQ326 Novartis social media posts on Q3 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ326 Novartis social media posts on Q3 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

Novartis avatar
Novartis@Novartis·Jul 21

#NVSQ226 Novartis social media posts on Q2 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ226 Novartis social media posts on Q2 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

Novartis avatar
Novartis@Novartis·Apr 28

#NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ126 Novartis social media posts on Q1 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

Novartis avatar
Novartis@Novartis·Feb 4

#NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

Tedros Adhanom Ghebreyesus avatar
⟳ Novartis retweeted
Tedros Adhanom Ghebreyesus@DrTedros·Jan 21

Delighted to announce the extension of the @WHO–@Novartis memorandum of understanding, continuing the provision of free multidrug therapy for #leprosy treatment and expanding support to include funding for single-dose rifampicin for post-exposure prophylaxis.   For 25 years, WHO and Novartis have partnered to interrupt the transmission and eliminate leprosy disease.   In 2024, #Jordan became the first country verified and acknowledged by WHO for elimination of leprosy showing when science, equity and partnership are aligned, disease elimination becomes within reach.   Thank you Novartis for your continued support and I look forward to further expand our collaboration to promote #HealthForAll. who.int/news/item/21-01-2026…

Novartis US avatar
⟳ Novartis retweeted
Novartis US@NovartisUS·10 Nov 2025

#News: Today marks a milestone in our $23 billion US expansion plan, as we announce the opening of a state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, CA. 🔗 go.novartis.social/47LONem

0:48